drugset / Trial / NCT05033912
A Study of CST-2032 in Subjects With Cognitive Impairment
RandomizedSequentialQuadruple-blindTreatment
Summary
This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.
Timeline
- Start
- 2021-10
- Primary completion
- 2022-03
- Completion
- 2022-05
Outcome
Outcome not reported
Stopped (Business): “Business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CST-2032 | Unknown | 1 mg | Oral |
| Subject | CST-2032 | Unknown | 3 mg | Oral |
| Subject | CST-2032 | Unknown | 9 mg | Oral |
| Background | CST-107 | Unknown | 3 mg | — |